We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alpine Immune Sciences Inc (ALPN) USD0.001

Sell:$35.27 Buy:$35.67 Change: $0.78 (2.21%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.78 (2.21%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.78 (2.21%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Contact details

188 East Blaine St., Suite 200
United States
+1 (206) 7884545

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.36 billion
Shares in issue:
65.54 million
United States
US dollar

Key personnel

  • Mitchell Gold
    Executive Chairman of the Board, Chief Executive Officer
  • Stanford Peng
    President, Head - Research and Development
  • Paul Rickey
    Chief Financial Officer, Senior Vice President, Corporate Secretary
  • Wolfgang Dummer
    Chief Medical Officer
  • Remy Durand
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.